Moderna Shares Dip 5% as CMV Vaccine Candidate Fails Phase 3 Trial

Modernas shares dropped 5% after the company announced its cytomegalovirus vaccine candidate failed to meet efficacy goals in a Phase 3 trial, impacting its developmental prospects.

• Modernas cytomegalovirus vaccine candidate, mRNA-1647, demonstrated disappointing efficacy rates against primary CMV infection, ranging from 6% to 23% in healthy women during Phase 3 trials.
• The failure to meet primary efficacy endpoints in the trial has led Moderna to discontinue its clinical development of the vaccine, raising concerns about preventing birth defects associated with CMV.
• Following the announcement, Modernas stock fell by 5% in after-hours trading, reflecting investor concerns about the future viability of the vaccine and its potential impact on the companys portfolio.